|Ms. Linda F. Powers J.D.||Chairperson, CEO, Pres & CFO||502k||N/A||1956|
|Dr. Alton L. Boynton||Founder, Chief Scientific Officer, Sec. & Director||325k||N/A||1945|
|Dr. Marnix L. Bosch M.B.A., Ph.D., MBA||Chief Technical Officer||375k||N/A||1959|
|Mr. Leslie J. Goldman||Sr. VP & Gen. Counsel||375k||N/A||1945|
|Mr. David Innes||VP of Investor Relations||N/A||N/A||N/A|
Northwest Biotherapeutics, Inc., a biotechnology company, discovers and develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Northwest Biotherapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 10. The pillar scores are Audit: 10; Board: 9; Shareholder Rights: 9; Compensation: 8.